Algorithms for diagnosis and treatment of gastroesophageal reflux disease

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Full Text

Restricted Access

About the authors

Igor V. Maev

Russian University of Medicine

Email: igormaev@rambler.ru
ORCID iD: 0000-0001-6114-564X

Dr.Sci. (Med.), Academician of the RAS, Professor, Honored Doctor of the Russian Federation, Honored Scientist of the Russian Federation, Head of the Department of Propaedeutics of Internal Medicine and Gastroenterology

Russian Federation, Moscow

Georgy L. Yurenev

Russian University of Medicine

Author for correspondence.
Email: yurenev@list.ru
ORCID iD: 0000-0001-8181-8813

Dr. Sci. (Med.), Professor, Department of Propaedeutics of Internal Medicine and Gastroenterology

Russian Federation, Moscow

Dmitry N. Andreev

Russian University of Medicine

Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-4007-7112

Cand. Sci. (Med.), Associate Professor, Department of Propaedeutics of Internal Medicine and Gastroenterology

Russian Federation, Moscow

Maria A. Ovsepyan

Russian University of Medicine

Email: proped2022@gmail.com
ORCID iD: 0000-0003-4511-6704

Teaching Assistant, Department of Propaedeutics of Internal Medicine and Gastroenterology

Russian Federation, Moscow

Elena V. Barkalova

Russian University of Medicine

Email: maslovaalena@mail.ru
ORCID iD: 0000-0001-5882-9397

Teaching Assistant, Department of Propaedeutics of Internal Medicine and Gastroenterology

Russian Federation, Moscow

References

  1. Ивашкин В.Т., Трухманов А.С., Маев И.В. и др. Диагностика и лечение гастроэзофагеальной рефлюксной болезни (Рекомендации Российской гастроэнтерологической ассоциации, Российского научного медицинского общества терапевтов, Российского общества профилактики неинфекционных заболеваний, Научного сообщества по изучению микробиома человека). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024;34(5):111–135. [Ivashkin V.T., Trukhmanov A.S., Maev I.V., et al. Diagnosis and Treatment of Gastroesophageal Reflux Disease (Clinical Guidelines of the Russian Gastroenterological Association, Russian Scientific Medical Society of Internal Medicine, Russian Society for the Prevention of Noncommunicable Diseases, Scientific Сommunity for Human Microbiome Research). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(5):111–135. (In Russ.)]. https://doi.org/10.22416/1382-4376-2024-34-5-111-135
  2. Yadlapati R., Gyawali C.P., Pandolfino J.E.; CGIT GERD Consensus Conference Participants. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: Expert review. Clin Gastroenterol Hepatol. 2022;20(5):984–94.e1. https://doi.org/10.1016/j.cgh.2022.01.025
  3. Gyawali C.P., Yadlapati R., Fass R., et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut. 2024 Jan 5;73(2):361-371. https://doi.org/10.1136/gutjnl-2023-330616
  4. Katz P.O., Dunbar K.B., Schnoll-Sussman F.H., et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am. J. Gastroenterol. 2022;117(1):27–56.
  5. Vakil N., van Zanten S.V., Kahrilas P., Dent J., Jones R.; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900–20. https://doi.org/10.1111/j.1572-0241.2006.00630.x
  6. Dekel R., Pearson T., Wendel C., et al. Assessment of oesophageal motor function in patients with dysphagia or chest pain — the Clinical Outcomes Research Initiative experience. Aliment Pharmacol Ther. 2003;18(11–12):1083–9. https://dx.doi.org/10.1046/j.1365-2036.2003.01772.x
  7. Eusebi L.H., Ratnakumaran R., Yuan Y., et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis. Gut. 2018;67(3):430–40. https://doi.org/10.1136/gutjnl-2016-313589
  8. Hampel H., Abraham N.S., El-Serag H.B. Meta-analysis: Obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med. 2005;143(3):199–211. https://doi.org/10.7326/0003-4819-143-3-200508020-00006
  9. Zhang Y., Chen S.H., Effect of Coffee on Gastroesophageal Reflux Disease. Food Sci Technol Res. 2013;19(1):1–6. https://doi.org/10.3136/fstr.19.1
  10. Kim J., Oh S.W., Myung S.K., et al. Association between coffee intake and gastroesophageal reflux disease: a meta-analysis. Dis Esophagus. 2014;27(4):311–317. https://doi.org/10.1111/dote.12099
  11. Овсепян М.А., Баркалова Е.В., Андреев Д.Н., Маев И.В. Оптимизация лечения больных гастроэзофагеальной рефлюксной болезнью: акцент на нутритивные факторы риска и диетологические подходы. Медицинский совет. 2023;17(8):51–58. [Ovsepian M.A., Barkalova E.V., Andreev D.N., Maev I.V. Optimizing the treatment of patients with gastroesophageal reflux disease: focus on nutritional risk factors and nutritional approaches. Meditsinskiy Sovet. 2023;17(8):51–58. (In Russ.)]. https://doi.org/10.21518/ms2023-124
  12. Васильев Ю.В. Язвенная болезнь, Helicobacter pylori и табакокурение: патогенетические аспекты и лечение больных. Экспериментальная и клинническая гастроэнтерология. 2008;8:12–8. [Vasiliev Yu.V. Peptic ulcer, Helicobacter pylori and tobacco smoking: pathogenetic aspects and treatment of patients. Eksperimental’naia i klinicheskaia gastroenterologiia=Experimental & clinical gastroenterology. 2008;8:12–8. (In Russ.)].
  13. Пахомова И.Г., Хорошинина Л.П. НПВП-индуцированная эзофагопатия: просто ГЭРБ или еще одна нозологическая единица? Фарматека. 2016;(15):39–43. [Pakhomova I.G., Khoroshinina L.P. NSAID-induced esophagopathy: just gerd or another disease entity? Farmateka. 2016;(15):39–43. (In Russ.)].
  14. Hunt R., Armstrong D., Katelaris P., et al. WGO Global Guidelines. GERD. World Gastroenterology Organisation, 2015. URL: https://www.worldgastroenterology.org/guidelines/gastroesophageal-reflux-disease/gastroesophageal-reflux-disease-gerd-russian
  15. Lundell L.R., Dent J., Bennett J.R., et al. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45(2):172–80. https://doi.org/10.1136/gut.45.2.172
  16. Shaheen N.J., Richter J.E. Barrett’s oesophagus. Lancet. 2009;373(9666):850–61. https://doi.org/10.1016/S0140-6736(09)60487-6
  17. Gonçalves E.S., Assumpção M.S., Servidoni M.F.C.P., et al. Multichannel intraluminal impedance-pH and psychometric properties in gastroesophageal reflux: Systematic review. J Pediatr (Rio J). 2020;96(6):673–85. https://doi.org/10.1016/j.jped.2020.01.005
  18. Frazzoni L., Frazzoni M., de Bortoli N., et al. Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. Ann Gastroenterol. 2018 Jan-Feb;31(1):1-7. https://doi.org/10.20524/aog.2017.0199
  19. Frazzoni M., Manta R., Mirante V.G., et al. Esophageal chemical clearance is impaired in gastro-esophageal reflux disease – a 24-h impedance-pH monitoring assessment. Neurogastroenterol Motil. 2013;25(5):399–406, e295. https://doi.org/10.1111/nmo.12080
  20. Woodland P., Shen Ooi J.L., Grassi F., et al. Superficial esophageal mucosal afferent nerves may contribute to reflux hypersensitivity in nonerosive reflux disease. Gastroenterology. 2017;153(5):1230–9. https://doi.org/10.1053/j.gastro.2017.07.017
  21. Маев И.В., Юренев Г.Л., Бурков С.Г. Многоликая ГЭРБ: проблемы и решения. М.: ГЭОТАР-Медиа, 2015. 386 с. [Maev I.V., Yurenev G.L., Burkov S.G. The many faces of GERD: problems and solutions. Moscow: GEOTAR-Media, 2015. 386 p. (In Russ.)].
  22. Aziz Q., Fass R., Gyawali C.P., et al. Functional Esophageal Disorders. Gastroenterology. 2016:S0016-5085(16)00178-5. https://doi.org/10.1053/j.gastro.2016.02.012
  23. Gyawali C.P., Tutuian R., Zerbib F., et al. Value of pH impedance monitoring while on twice-daily proton pump inhibitor therapy to identify need for escalation of reflux management. Gastroenterology. 2021;161(5):1412–22. https://doi.org/10.1053/j.gastro.2021.07.004
  24. Zerbib F., Bredenoord A.J., Fass R., et al. ESNM/ANMS consensus paper: Diagnosis and management of refractory gastroesophageal reflux disease. Neurogastroenterol Motil. 2021;33(4):e14075. https://doi.org/10.1111/nmo.14075
  25. Naik R.D., Meyers M.H., Vaezi M.F. Treatment of refractory gastroesophageal reflux disease. Gastroenterol Hepatol (N Y). 2020;16(4): 196–205.
  26. Маев И.В., Трухманов А.С., Шептулин А.А. и др. Роль нарушений моторики в патогенезе функциональных расстройств желудочно-кишечного тракта и современные возможности их лечения (Резолюция Экспертного совета и обзор литературы). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(6):7–14. [Maev I.V., Trukhmanov A.S., Sheptulin A.A., et al. The role of motility impairment in the pathogenesis of functional disorders of the gastrointestinal tract and modern possibilities for their treatment (Resolution of an Expert Council and literature review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):7–14. (In Russ.)]. https://doi.org/10.22416/1382-4376-2019-29-6-7-14
  27. Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. [Simanenkov V.I., Maev I.V., Tkacheva O.N., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.)]. https://doi.org/10.15829/1728-8800-2021-2758
  28. Трухманов А.С., Румянцева Д.Е. Ребамипид и ингибиторы протонной помпы: преимущества совместного применения. Вопросы детской диетологии. 2022;20(1):42–51. [Trukhmanov A.S., Rumyantseva D.E. Rebamipideand proton pump inhibitors: Benefits of combined use. Pediatric Nutrition. 2022;20(1):42–51. (In Russ.)]. https://doi.org/10.20953/1727-5784-2022-1-42-51
  29. Alexander H.C., Hendler R.S., Seymour N.E., Shires G.T. 3rd. Laparoscopic treatment of gastroesophageal reflux disease. Am Surg. 1997;63(5):434–40.
  30. Инструкция по медицинскому применению лекарственного препарата Гевискон® суспензия для приема внутрь. Рег. уд. №: ЛС-002444 от 29.12.2011. [Instructions for medical use of the medicinal product Gaviscon® suspension for oral administration. Reg. ID. No.: LS-002444 dated 29.12.2011. (In Russ.)].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. GERD diagnosis algorithm

Download (1MB)
Indexing metadata
3. GERD treatment algorithm

Download (510KB)
Indexing metadata

Copyright (c) 2025 Bionika Media